Edap Tms S.A. $EDAP Shares Purchased by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA significantly increased its holdings in Edap Tms by 7,063.7% in the first quarter, acquiring an additional 720,499 shares and owning about 1.97% of the company valued at $1,324,000.
• Analysts have shifted their outlook on Edap Tms, with Piper Sandler downgrading the stock from an "overweight" to a "neutral" rating, reflecting a consensus rating of "Hold" and an average price target of $8.50.
• Edap Tms currently has a market cap of $103.20 million, with a price range over the last year between $1.21 and $3.77, indicating volatility in its stock price.

Banque Transatlantique SA raised its stake in shares of Edap Tms S.A. (NASDAQ:EDAP - Free Report) by 7,063.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 730,699 shares of the medical equipment provider's stock after acquiring an additional 720,499 shares during the period. Banque Transatlantique SA owned approximately 1.97% of Edap Tms worth $1,324,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of EDAP. Jane Street Group LLC raised its stake in shares of Edap Tms by 174.7% during the 4th quarter. Jane Street Group LLC now owns 31,361 shares of the medical equipment provider's stock worth $69,000 after buying an additional 73,361 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Edap Tms by 111.5% during the 4th quarter. BNP Paribas Financial Markets now owns 48,650 shares of the medical equipment provider's stock worth $108,000 after buying an additional 25,650 shares in the last quarter. Millennium Management LLC raised its stake in shares of Edap Tms by 218.5% during the 4th quarter. Millennium Management LLC now owns 48,915 shares of the medical equipment provider's stock worth $108,000 after buying an additional 33,558 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of Edap Tms by 33.9% during the 1st quarter. Cetera Investment Advisers now owns 75,000 shares of the medical equipment provider's stock worth $147,000 after buying an additional 19,000 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its stake in shares of Edap Tms by 48.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 160,800 shares of the medical equipment provider's stock worth $355,000 after buying an additional 52,500 shares in the last quarter. 62.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Wall Street Zen assumed coverage on Edap Tms in a research note on Thursday, May 15th. They set a "hold" rating for the company. Piper Sandler downgraded Edap Tms from an "overweight" rating to a "neutral" rating in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, Edap Tms currently has a consensus rating of "Hold" and an average target price of $8.50.

Edap Tms Trading Up 5.6%

Shares of EDAP stock traded up $0.14 during mid-day trading on Monday, hitting $2.66. 103,625 shares of the company's stock were exchanged, compared to its average volume of 90,938. Edap Tms S.A. has a fifty-two week low of $1.21 and a fifty-two week high of $3.29. The stock has a 50-day simple moving average of $1.58 and a two-hundred day simple moving average of $1.82. The company has a quick ratio of 1.05, a current ratio of 1.51 and a debt-to-equity ratio of 0.04. The stock has a market cap of $99.46 million, a price-to-earnings ratio of -4.36 and a beta of -0.21.

About Edap Tms

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology.